The TB Disease Vaccine Market includes multiple vaccine technologies, indications, dosage formats, administration routes, and target populations. WiseGuyReports identifies BCG, live attenuated, recombinant protein, and polysaccharide vaccines as key technology categories within the global market.

BCG remains an important component of tuberculosis prevention programs, particularly for newborns and children. At the same time, research into newer vaccine platforms is increasing as developers seek improved efficacy and broader protection. Recombinant protein and live attenuated approaches are receiving attention because of their potential to provide enhanced protection against different stages of tuberculosis infection.

The market can also be segmented by indication, including prevention of TB infection, treatment of latent TB infection, and treatment of active tuberculosis. By dosage, the market includes single-dose and multiple-dose vaccines. Intradermal, subcutaneous, and intramuscular injections represent major administration routes.

Target populations include newborns, infants, children, adolescents, and adults. Newborn and infant vaccination remains particularly important because early immunization can help protect vulnerable populations from severe forms of tuberculosis.

Regional segmentation covers North America, Europe, Asia-Pacific, South America, and the Middle East and Africa.

Future market development is expected to depend heavily on improved vaccine technologies, clinical research, accessibility, affordability, and the ability of healthcare systems to implement effective vaccination programs.